GLP-1 clinical trials enrolling now. Find one near you.
78 GLP-1 clinical trials covering 53 conditions are recruiting across 46 US states as of August 21, 2026. You pay nothing for the medication.
Not sure which clinical trial fits you? Answer no more than 8 short questions, one per screen. We show you the clinical trials that fit your age, where you live, and the rules each one sets.
In every clinical trial here, the study medication and trial visits cost you nothing, and many pay you for your time. Some participants get a placebo, assigned at random.
Full title: A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)Study ID: NCT07165028Phase: Phase 3Sponsor: Eli Lilly and CompanyStudy drug: retatrutideSites: 142 US
Full title: A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightStudy ID: NCT07253285Phase: Phase 3Sponsor: Novo Nordisk A/SStudy drug: cagrilintideSites: 34 US
Full title: A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or WithoutStudy ID: NCT07564414Phase: Phase 3Sponsor: Novo Nordisk A/SStudy drug: cagrisemaSites: 99 US
Full title: LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver FibrosStudy ID: NCT06632444Phase: Phase 3Sponsor: Boehringer IngelheimStudy drug: survodutideSites: 165 US
Full title: LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have CirrhosisStudy ID: NCT06632457Phase: Phase 3Sponsor: Boehringer IngelheimStudy drug: survodutideSites: 126 US
Full title: A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood SugarStudy ID: NCT07754461Phase: Phase 3Sponsor: Boehringer IngelheimStudy drug: survodutideSites: 89 US
Full title: A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)Study ID: NCT06672549Phase: Phase 3Sponsor: Eli Lilly and CompanyStudy drug: orforglipronSites: 51 US
Full title: Efficacy and Safety of Orforglipron in Participants With Peripheral Artery DiseaseStudy ID: NCT07223593Phase: Phase 3Sponsor: Eli Lilly and CompanyStudy drug: orforglipronSites: 35 US
Full title: A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the KneeStudy ID: NCT07153471Phase: Phase 3Sponsor: Eli Lilly and CompanyStudy drug: orforglipronSites: 26 US
Full title: A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or OverweightStudy ID: NCT07202884Phase: Phase 3Sponsor: Eli Lilly and CompanyStudy drug: orforglipronSites: 21 US
Full title: Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in AdultsStudy ID: NCT07575399Phase: Phase 3Sponsor: AmgenStudy drug: Maridebart CafraglutideSites: 43 US
Full title: Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightStudy ID: NCT06937099Phase: Phase 3Sponsor: Eli Lilly and CompanyStudy drug: tirzepatideSites: 35 US
Full title: Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and ObeStudy ID: NCT06937086Phase: Phase 3Sponsor: Eli Lilly and CompanyStudy drug: tirzepatideSites: 37 US
Full title: Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Study ID: NCT07284979Phase: Phase 3Sponsor: KaileraStudy drug: KAI-9531Sites: 27 US
Full title: A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine AStudy ID: NCT07662213Phase: Phase 3Sponsor: AstraZenecaStudy drug: semaglutideSites: 63 US
Full title: A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related ComorbiditiesStudy ID: NCT06672939Phase: Phase 3Sponsor: Eli Lilly and CompanyStudy drug: orforglipronSites: 14 US
Full title: A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightStudy ID: NCT06143956Phase: Phase 2Sponsor: Eli Lilly and CompanyStudy drug: LY3305677Sites: 50 US
Full title: A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or TirzepatideStudy ID: NCT06897475Phase: Phase 2Sponsor: Eli Lilly and CompanyStudy drug: LY3457263Sites: 25 US
Full title: A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 DiabetesStudy ID: NCT07668388Phase: Phase 2Sponsor: Novo Nordisk A/SStudy drug: UBT251Sites: 25 US
Full title: A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With ObesityStudy ID: NCT07639021Phase: Phase 2Sponsor: Novo Nordisk A/SStudy drug: NNC0662-0419Sites: 24 US
Full title: A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and OStudy ID: NCT06864026Phase: Phase 4Sponsor: Eli Lilly and CompanyStudy drug: tirzepatideSites: 53 US
Full title: A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With ModeStudy ID: NCT06857942Phase: Phase 4Sponsor: Eli Lilly and CompanyStudy drug: tirzepatideSites: 40 US
Full title: A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 DiabetesStudy ID: NCT07415954Phase: Phase 2Sponsor: Novo Nordisk A/SStudy drug: NNC0662-0419Sites: 23 US
Full title: Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body WeightStudy ID: NCT07770841Phase: Phase 3Sponsor: Novo Nordisk A/SStudy drug: semaglutideSites: 16 US
Full title: A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)Study ID: NCT06439277Phase: Phase 3Sponsor: Eli Lilly and CompanyStudy drug: tirzepatideSites: 14 US
Full title: Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)Study ID: NCT07218354Phase: Phase 3Sponsor: VA Office of Research and DevelopmentStudy drug: semaglutideSites: 19 US
Full title: A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic KidnStudy ID: NCT06717698Phase: Phase 2Sponsor: Novo Nordisk A/SStudy drug: NNC0519-0130Sites: 18 US
Full title: Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based TheStudy ID: NCT07502508Phase: Phase 2Sponsor: Biomea Fusion Inc.Study drug: icovamenib 100 mgSites: 17 US
Full title: PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 DiabetesStudy ID: NCT05390892Phase: Phase 4Sponsor: Brigham and Women's HospitalStudy drug: semaglutideSites: 36 US
Full title: A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist UseStudy ID: NCT07446439Phase: Phase 3Sponsor: Vanda PharmaceuticalsStudy drug: TradipitantSites: 10 US
Full title: Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor AgonistStudy ID: NCT07446998Phase: Phase 2Sponsor: Veru Inc.Study drug: semaglutideSites: 14 US
Full title: A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 DiabetesStudy ID: NCT07724340Phase: Phase 2Sponsor: Antag TherapeuticsStudy drug: AT673 low doseSites: 8 US
Full title: Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse EventsStudy ID: NCT07607587Phase: Phase 1Sponsor: Novo Nordisk A/SStudy drug: cagrilintideSites: 11 US
Full title: A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLDStudy ID: NCT07527910Phase: Phase 2Sponsor: Regeneron PharmaceuticalsStudy drug: tirzepatideSites: 6 US
Full title: Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without DiabetesStudy ID: NCT07685808Phase: Phase 2Sponsor: Regeneron PharmaceuticalsStudy drug: olatorepatideSites: 5 US
Full title: A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to DietStudy ID: NCT07184086Phase: Phase 1Sponsor: Novo Nordisk A/SStudy drug: cagrisemaSites: 2 US
Full title: A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device iStudy ID: NCT07107334Phase: Phase 2Sponsor: University of FloridaStudy drug: orforglipronSites: 1 US
Full title: Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset DiabetesStudy ID: NCT06246799Phase: Phase 3Sponsor: The University of Texas Health Science Center at San AntonioStudy drug: tirzepatideSites: 2 US
Full title: Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use DisorderStudy ID: NCT06651177Phase: Phase 2Sponsor: T. John Winhusen, PhDStudy drug: tirzepatideSites: 9 US
Full title: Type 1 Diabetes Impacts of Semaglutide on Cardiovascular OutcomesStudy ID: NCT05819138Phase: Phase 3Sponsor: University of Colorado, DenverStudy drug: semaglutideSites: 2 US
Full title: Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial FibrillationStudy ID: NCT06499857Phase: Phase 3Sponsor: University of ChicagoStudy drug: semaglutideSites: 2 US
Full title: Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary SyndromeStudy ID: NCT05819853Phase: Phase 3Sponsor: University of Colorado, DenverStudy drug: semaglutideSites: 1 US
Full title: Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With DiabetesStudy ID: NCT07428746Phase: Phase 3Sponsor: Emory UniversityStudy drug: semaglutideSites: 1 US
Full title: Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-CessationStudy ID: NCT07092618Phase: Phase 2Sponsor: AgelessRxStudy drug: MetforminSites: 1 US
Full title: A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With ObesityStudy ID: NCT07728383Phase: Phase 4Sponsor: Gila Therapeutics, Inc.Study drug: semaglutideSites: 1 US
Full title: Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast CancerStudy ID: NCT06518837Phase: Phase 2Sponsor: Rutgers, The State University of New JerseyStudy drug: tirzepatideSites: 7 US
Full title: GLP-1R Agonist Treatment for Opioid Use DisorderStudy ID: NCT06548490Phase: Phase 2Sponsor: Milton S. Hershey Medical CenterStudy drug: semaglutideSites: 4 US
Full title: Focusing on the Menopausal Transition to Improve Mid-Life Women's HealthStudy ID: NCT06975111Phase: Phase 2Sponsor: University of Colorado, DenverStudy drug: semaglutideSites: 3 US
Full title: Multi-Site Trial of Tirzepatide for Smoking CessationStudy ID: NCT07602699Phase: Phase 2Sponsor: University of Southern CaliforniaStudy drug: tirzepatideSites: 4 US
Full title: Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese PartStudy ID: NCT07673900Phase: Phase 1Sponsor: Terrestrial Bio, Inc.Study drug: semaglutideSites: 1 US
Full title: Study of Tirzepatide for Recovery and Alcohol Use ManagementStudy ID: NCT06727331Phase: Phase 2Sponsor: Brigham and Women's HospitalStudy drug: tirzepatideSites: 2 US
Full title: Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in PeopStudy ID: NCT07225816Phase: Phase 1Sponsor: Novo Nordisk A/SStudy drug: semaglutideSites: 1 US
Full title: Sit Less, Interact and Move More (SLIMM) 2 StudyStudy ID: NCT05173714Phase: Phase 2Sponsor: Srinvasan BeddhuStudy drug: semaglutideSites: 2 US
Full title: Semaglutide for Post-Smoking Cessation Weight ManagementStudy ID: NCT06173778Phase: Phase 2Sponsor: The University of Texas Health Science Center, HoustonStudy drug: semaglutideSites: 2 US
Full title: A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese AdultsStudy ID: NCT07465965Phase: Phase 1Sponsor: Shanghai World Leader Pharmaceutical Co., Ltd.Study drug: semaglutideSites: 1 US
Full title: Therapeutic Strategies for Microvascular Dysfunction in Type 1 DiabetesStudy ID: NCT05478707Phase: Phase 2Sponsor: AdventHealth Translational Research InstituteStudy drug: dulaglutideSites: 1 US
Full title: Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist TherapyStudy ID: NCT06903923Phase: Phase 2Sponsor: University of VirginiaStudy drug: GLP-1 receptor agonistSites: 1 US
Full title: TIRzepatide for the Treatment of Obesity in Patients With Atrial FibrillationStudy ID: NCT06802081Phase: Phase 2Sponsor: The Cleveland ClinicStudy drug: tirzepatideSites: 1 US
Full title: Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor MalignanciesStudy ID: NCT04114136Phase: Phase 2Sponsor: Dan ZandbergStudy drug: Nivolumab or Pembrolizumab (dependent upon approved indication)Sites: 1 US
Full title: Glucagon-Like Peptide-1 Receptor Agonist in ADPKDStudy ID: NCT06582875Phase: Phase 2Sponsor: University of Colorado, DenverStudy drug: tirzepatideSites: 1 US
Full title: Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating DisorderStudy ID: NCT06847399Phase: Phase 2Sponsor: Johns Hopkins UniversityStudy drug: tirzepatideSites: 1 US
Full title: Moving Beyond Inflammation as a Therapeutic Target for Crohn's DiseaseStudy ID: NCT06976853Phase: Phase 2Sponsor: Washington University School of MedicineStudy drug: tirzepatideSites: 3 US
Full title: Effects of Tirzepatide on Muscle and Vascular Health in Obese Older AdultsStudy ID: NCT06811324Phase: Phase 2Sponsor: The University of Texas Health Science Center at San AntonioStudy drug: tirzepatideSites: 1 US
Full title: GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIVStudy ID: NCT07221214Phase: Phase 2Sponsor: Vanderbilt University Medical CenterStudy drug: semaglutideSites: 1 US
Full title: The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 DiabetesStudy ID: NCT06976619Phase: Phase 2Sponsor: Mayo ClinicStudy drug: liraglutideSites: 1 US
Full title: Trial of Semaglutide for Diabetic Kidney Disease in Type 1 DiabetesStudy ID: NCT05822609Phase: Phase 2Sponsor: University of WashingtonStudy drug: semaglutideSites: 3 US
Full title: Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With ObesityStudy ID: NCT07228741Phase: Phase 2Sponsor: St. Jude Children's Research HospitalStudy drug: tirzepatideSites: 1 US
Full title: NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black IndividualsStudy ID: NCT04055428Phase: Phase 2Sponsor: University of Alabama at BirminghamStudy drug: Sacubitril, Valsartan 97-103 mg Oral TabletSites: 1 US
Full title: Tirzepatide in MetALDStudy ID: NCT07046819Phase: Phase 2Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA)Study drug: tirzepatideSites: 1 US
Full title: Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/ObesityStudy ID: NCT05912621Phase: Phase 2Sponsor: Stanford UniversityStudy drug: tirzepatideSites: 1 US
Full title: Prolongation of GLP-1 Adherence When Using Continuous Glucose MonitoringStudy ID: NCT06668935Phase: Not ApplicableSponsor: Abbott Diabetes CareStudy drug: investigational drugSites: 2 US
Full title: Tirzepatide for Alcohol Use DisorderStudy ID: NCT06994338Phase: Phase 2Sponsor: University of Southern CaliforniaStudy drug: tirzepatideSites: 1 US
Full title: Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With ObesityStudy ID: NCT05933499Phase: Phase 2Sponsor: Massachusetts General HospitalStudy drug: tirzepatideSites: 1 US
Full title: Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver TransplantStudy ID: NCT05424003Phase: Phase 2Sponsor: University of VirginiaStudy drug: semaglutideSites: 1 US
Full title: Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 SemaglutideStudy ID: NCT07040592Phase: Phase 2Sponsor: Yale UniversityStudy drug: semaglutideSites: 1 US
The data comes from ClinicalTrials.gov, the US federal registry for clinical research. We pull active and pre-active GLP-1 clinical trials (semaglutide, tirzepatide, liraglutide, retatrutide, survodutide, orforglipron, cagrisema and related molecules) plus studies of GLP-1 effects on conditions like obesity, type 2 diabetes, MASH, sleep apnea, CKD, and cardiovascular disease.
Every Monday we check these listings against ClinicalTrials.gov. Before you contact a site, click through to its registry record and confirm the clinical trial is still recruiting. For the wider picture on getting a GLP-1 at no cost, see how to get a GLP-1 for free.
How to enroll in a clinical trial
Find a clinical trial below or take the matching quiz. Read the eligibility criteria. The key inclusion and exclusion items are the ones the trial coordinator will check first.
Find a site location near you. We list every US site with city, state, and contact information when the sponsor publishes it.
Contact the site directly using the phone or email on the trial page. Tell them you read about the trial on GLP Chart and you want to be screened.
Screening typically involves a phone call, a clinic visit, and sometimes blood work. Most trials cover the cost of screening and trial-related medical care. Some sites compensate participants for their time; the trial coordinator explains what each site offers.
If you do not qualify for the trial you contacted, ask the site coordinator about other trials they run. Many sites run multiple GLP-1 studies at once and can route you to a better fit.
If a trial is not a fit and you need treatment now, the GLP-1 cost guide lays out what every legitimate cash-pay path costs at maintenance dose, starting at $149 a month for compounded semaglutide.
A few legal notes
GLP Chart is not affiliated with any of the sponsors or sites listed. We do not enroll patients in trials. We do not receive payment for any individual enrollment as of the date of this directory. Future commercial relationships with clinical research organizations may exist; if so they will be disclosed here and in the affiliate disclosure.
Participating in a clinical trial is a serious medical decision. Talk to your existing healthcare provider before enrolling. Trial coordinators are required by federal regulation to walk you through informed consent before you join.
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas. About this site · LinkedIn · Contact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.
Clinical trials can take months to enroll.
Every Monday we email where GLP-1s are cheapest to buy in the meantime.
You're in.We'll email you the moment something changes.